JNJ 1661010
JNJ-1661010 is a chemical compound that has been investigated for its potential therapeutic effects in various medical conditions. It is primarily known for its role as a selective antagonist of the CB2 receptor, which is part of the endocannabinoid system.
Pharmacology[edit | edit source]
JNJ-1661010 is a selective antagonist of the CB2 receptor, which is predominantly expressed in the immune system. Unlike the CB1 receptor, which is found mainly in the central nervous system, the CB2 receptor is involved in modulating immune responses and inflammation. By blocking the CB2 receptor, JNJ-1661010 may have potential applications in treating conditions characterized by excessive inflammation or immune system dysregulation.
Mechanism of Action[edit | edit source]
The mechanism of action of JNJ-1661010 involves its binding to the CB2 receptor, thereby inhibiting the receptor's activation by endogenous cannabinoids such as 2-AG and Anandamide. This inhibition can lead to a reduction in the pro-inflammatory signaling pathways that are typically activated by CB2 receptor stimulation.
Potential Therapeutic Applications[edit | edit source]
Research into JNJ-1661010 has suggested several potential therapeutic applications, including:
- Autoimmune diseases: By modulating immune responses, JNJ-1661010 may be beneficial in conditions such as rheumatoid arthritis and multiple sclerosis.
- Chronic pain: The compound's ability to influence inflammatory pathways may make it useful in managing chronic pain conditions.
- Neuroinflammation: JNJ-1661010 could potentially be used to treat neuroinflammatory conditions, given the role of the CB2 receptor in the immune system.
Research and Development[edit | edit source]
JNJ-1661010 is still under investigation, and its safety and efficacy in humans have not been fully established. Preclinical studies have shown promising results, but further research is needed to determine its potential as a therapeutic agent.
Also see[edit | edit source]
- Cannabinoid receptor type 1
- Endocannabinoid system
- Cannabinoid receptor type 2
- 2-Arachidonoylglycerol
- Anandamide
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
